-
1
-
-
84866619380
-
Cancer drugs and the heart: importance and management
-
[Epub ahead of print].
-
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2012. [Epub ahead of print].
-
(2012)
Eur Heart J.
-
-
Suter, T.M.1
Ewer, M.S.2
-
2
-
-
84873983357
-
-
National Cancer Institute. Cancer therapy evaluation program. [on-line]
-
National Cancer Institute. Cancer therapy evaluation program. [on-line] http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4e30e992.pdf.
-
-
-
-
3
-
-
40749087694
-
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems
-
Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008; 14: 14-24.
-
(2008)
Clin Cancer Res.
, vol.14
, pp. 14-24
-
-
Bird, B.R.1
Swain, S.M.2
-
4
-
-
0018716636
-
Risk factors for doxorubicin-induced congestive heart failure
-
Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 710-717.
-
(1979)
Ann Intern Med.
, vol.91
, pp. 710-717
-
-
Von Hoff, D.D.1
Layard, M.W.2
Basa, P.3
-
5
-
-
0033855860
-
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
-
Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000; 36: 517-522.
-
(2000)
J Am Coll Cardiol.
, vol.36
, pp. 517-522
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
-
6
-
-
0035985276
-
Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy
-
Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy. Ann Oncol. 2002; 13: 710-715.
-
(2002)
Ann Oncol.
, vol.13
, pp. 710-715
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
-
7
-
-
2942522528
-
Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
-
Cardinale D, Sandri MT, Colombo A et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109: 2749-2754.
-
(2004)
Circulation.
, vol.109
, pp. 2749-2754
-
-
Cardinale, D.1
Sandri, M.T.2
Colombo, A.3
-
8
-
-
17644388763
-
Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography
-
Pichon MF, Cvitkovic F, Hacene K et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005; 19: 567-576.
-
(2005)
In Vivo.
, vol.19
, pp. 567-576
-
-
Pichon, M.F.1
Cvitkovic, F.2
Hacene, K.3
-
9
-
-
0025765631
-
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens
-
Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991; 9: 1215-1223.
-
(1991)
J Clin Oncol.
, vol.9
, pp. 1215-1223
-
-
Braverman, A.C.1
Antin, J.H.2
Plappert, M.T.3
-
10
-
-
0022806838
-
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
-
Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986; 68: 1114-1118.
-
(1986)
Blood.
, vol.68
, pp. 1114-1118
-
-
Goldberg, M.A.1
Antin, J.H.2
Guinan, E.C.3
-
11
-
-
0027455066
-
High-dose ifosfamide is associated with severe, reversible cardiac dysfunction
-
Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118: 31-36.
-
(1993)
Ann Intern Med.
, vol.118
, pp. 31-36
-
-
Quezado, Z.M.1
Wilson, W.H.2
Cunnion, R.E.3
-
12
-
-
21144435932
-
Adjuvant docetaxel for node-positive breast cancer
-
Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302-2313.
-
(2005)
N Engl J Med.
, vol.352
, pp. 2302-2313
-
-
Martin, M.1
Pienkowski, T.2
Mackey, J.3
-
13
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
-
(2011)
N Engl J Med.
, vol.365
, Issue.14
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
14
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
-
(2005)
N Engl J Med.
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
15
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
-
(2005)
N Engl J Med.
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
16
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
-
(2001)
N Engl J Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
17
-
-
29744442709
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
-
Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 7811-7819
-
-
Tan-Chiu, E.1
Yothers, G.2
Romond, E.3
-
18
-
-
41649083764
-
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
-
Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 1231-1238
-
-
Perez, E.A.1
Suman, V.J.2
Davidson, N.E.3
-
19
-
-
34548531901
-
Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial
-
Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007; 25: 3859-3865.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 3859-3865
-
-
Suter, T.M.1
Procter, M.2
van Veldhuisen, D.J.3
-
20
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
-
(2006)
N Engl J Med.
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
-
21
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
-
(2007)
N Engl J Med.
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
22
-
-
44949253343
-
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
-
Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83: 679-686.
-
(2008)
Mayo Clin Proc.
, vol.83
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
-
23
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
-
(2007)
N Engl J Med.
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
24
-
-
78650383580
-
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
-
Eschenhagen T, Force T, Ewer M et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13: 1-10.
-
(2011)
Eur J Heart Fail.
, vol.13
, pp. 1-10
-
-
Eschenhagen, T.1
Force, T.2
Ewer, M.3
-
25
-
-
61749084637
-
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
-
Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009; 100: 684-692.
-
(2009)
Br J Cancer.
, vol.100
, pp. 684-692
-
-
Jones, A.L.1
Barlow, M.2
Barrett-Lee, P.J.3
-
26
-
-
61449181370
-
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations
-
Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
-
(2009)
Oncologist
, vol.14
, pp. 1-11
-
-
Martin, M.1
Esteva, F.J.2
Alba, E.3
-
27
-
-
78649907467
-
Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage
-
Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12: 404-410.
-
(2010)
Curr Hypertens Rep.
, vol.12
, pp. 404-410
-
-
Geisberg, C.A.1
Sawyer, D.B.2
-
28
-
-
77957567061
-
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation
-
Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28: 3910-3916.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3910-3916
-
-
Cardinale, D.1
Colombo, A.2
Torrisi, R.3
-
29
-
-
33845402341
-
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition
-
Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006; 114: 2474-2481.
-
(2006)
Circulation.
, vol.114
, pp. 2474-2481
-
-
Cardinale, D.1
Colombo, A.2
Sandri, M.T.3
-
31
-
-
33845206791
-
Protective effects of carvedilol against anthracyclines-induced cardiomyopathy
-
Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258-2262.
-
(2006)
J Am Coll Cardiol.
, vol.48
, pp. 2258-2262
-
-
Kalay, N.1
Basar, E.2
Ozdogru, I.3
-
32
-
-
28044442932
-
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
-
Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104: 2492-2498.
-
(2005)
Cancer.
, vol.104
, pp. 2492-2498
-
-
Nakamae, H.1
Tsumura, K.2
Terada, Y.3
-
33
-
-
77957241407
-
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion
-
Huh WW, Jaffe N, Durand JB et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion. Pediatr Hematol Oncol. 2010; 27: 546-557.
-
(2010)
Pediatr Hematol Oncol.
, vol.27
, pp. 546-557
-
-
Huh, W.W.1
Jaffe, N.2
Durand, J.B.3
-
34
-
-
0036018917
-
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil
-
Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002; 13: 484-485.
-
(2002)
Ann Oncol.
, vol.13
, pp. 484-485
-
-
Van Cutsem, E.1
Hoff, P.M.2
Blum, J.L.3
-
35
-
-
0025799973
-
Cardiac disturbances during the administration of taxol
-
Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9: 1704-1712.
-
(1991)
J Clin Oncol.
, vol.9
, pp. 1704-1712
-
-
Rowinsky, E.K.1
McGuire, W.P.2
Guarnieri, T.3
-
36
-
-
38049095554
-
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials
-
Cuppone F, Bria E, Verma S et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials. Cancer 2008; 112: 260-267.
-
(2008)
Cancer
, vol.112
, pp. 260-267
-
-
Cuppone, F.1
Bria, E.2
Verma, S.3
-
37
-
-
55949123335
-
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
-
Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 5204-5212.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 5204-5212
-
-
Schmidinger, M.1
Zielinski, C.C.2
Vogl, U.M.3
-
38
-
-
34250365240
-
Mechanisms of adverse effects of anti-VEGF therapy for cancer
-
Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96: 1788-1795.
-
(2007)
Br J Cancer.
, vol.96
, pp. 1788-1795
-
-
Kamba, T.1
McDonald, D.M.2
-
39
-
-
34249294557
-
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
-
Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7: 475-485.
-
(2007)
Nat Rev Cancer.
, vol.7
, pp. 475-485
-
-
Verheul, H.M.1
Pinedo, H.M.2
-
40
-
-
33645449812
-
Mechanisms of hypertension associated with BAY 43-9006
-
Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24: 1363-1369.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 1363-1369
-
-
Veronese, M.L.1
Mosenkis, A.2
Flaherty, K.T.3
-
42
-
-
40249094483
-
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
-
Curigliano G, Spitaleri G, Fingert HJ et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008; 44(4): 494-500.
-
(2008)
Eur J Cancer.
, vol.44
, Issue.4
, pp. 494-500
-
-
Curigliano, G.1
Spitaleri, G.2
Fingert, H.J.3
-
43
-
-
0035818552
-
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
-
Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2001; 135: 842-843.
-
(2001)
Ann Intern Med.
, vol.135
, pp. 842-843
-
-
Barbey, J.T.1
Soignet, S.2
-
44
-
-
0041352835
-
Asymptomatic cardiac disease following mediastinal irradiation
-
Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42: 743-749.
-
(2003)
J Am Coll Cardiol.
, vol.42
, pp. 743-749
-
-
Heidenreich, P.A.1
Hancock, S.L.2
Lee, B.K.3
-
45
-
-
27744581889
-
Diastolic dysfunction after mediastinal irradiation
-
Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005; 150: 977-982.
-
(2005)
Am Heart J.
, vol.150
, pp. 977-982
-
-
Heidenreich, P.A.1
Hancock, S.L.2
Vagelos, R.H.3
-
46
-
-
78751511293
-
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation
-
Galper SL, Yu JB, Mauch PM et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117(2): 412-418.
-
(2011)
Blood
, vol.117
, Issue.2
, pp. 412-418
-
-
Galper, S.L.1
Yu, J.B.2
Mauch, P.M.3
|